Asia's First Xenotransplanted Kidney Recipient Exceeds 30 Postoperative Days, Meets Discharge Criteria
Release time:
2025-04-11
On April 8 (Tuesday), Xijing Hospital of Air Force Medical University announced a major breakthrough in Asia’s first gene-edited pig kidney transplant for a patient with end-stage renal disease. The patient has maintained stable kidney function for 32 days post-surgery and met discharge standards. This achievement marks a milestone in China’s clinical research on xenotransplantation, offering new hope for patients with terminal kidney disease.
Overcoming Challenges: Stable Vital Signs
Under the guidance of Academician Dou Kefeng from the Chinese Academy of Sciences, a multidisciplinary team led by Dr. Qin Weijun from the hospital’s urology department successfully transplanted a gene-edited pig kidney into the patient on March 6. The surgical team addressed critical hurdles unique to xenotransplantation—immune rejection, coagulation disorders, and pathogen risks—through three innovative strategies: precise immunosuppression, coagulation regulation, and infection control.
Post-surgery, the patient’s vital signs remained stable, with serum creatinine levels maintained between 66-110 μmol/L and 24-hour urine output stabilized at 1800-2600 ml. Continuous monitoring and tailored treatment adjustments ensured smooth recovery.
“This breakthrough demonstrates new clinical possibilities for treating end-stage renal disease and confirms the feasibility of xenotransplantation, providing critical theoretical and technical foundations for future applications,” stated Academician Dou Kefeng.
How Pig Organs Could "Cross Species" to Save Lives
Xenotransplantation—the transfer of organs across species—is seen as a promising solution to the global shortage of human donor organs. While primates like chimpanzees were initially tested as donors, their use proved impractical.
Pigs, however, offer distinct advantages: their organs are structurally and functionally similar to humans, pose lower zoonotic disease risks, and are cost-effective to breed. Yet two major barriers remain: porcine endogenous retroviruses (PERVs) and hyperacute immune rejection.
Advances in gene-editing and immunology now enable scientists to delete risky genes in pigs and insert human genes, enhancing transplant compatibility and long-term survival prospects.
Recent breakthroughs in gene-edited pig organ transplants continue to drive progress. As this technology matures, it holds promise to address the global organ shortage crisis and usher in new hope for human health.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.